Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
AssigneeWashington University
InventorsJohn F. DiPersio, Matthew Cooper
Life of this patent
Estimating the term…
Abstract
The present disclosure provides the use of fratricide-resistant chimeric antigen receptor T (CAR-T) cells targeting antigens expressed by T cell malignancies.
Claims29
1-20. (canceled)
A process for producing a population of anti-CD7-CAR (chimeric antigen receptor)-expressing human T cells by multiplexed editing, the process comprising:
- (a) expressing in a population of activated human T cells a CRISPR/Cas editing system;
- (b) contacting the population of activated human T cells of step (a) with at least two guide polynucleotides, each targeting a polynucleotide encoding a different protein of interest, wherein the proteins are CD7 and TRAC (T cell receptor alpha chain);
- (c) modifying at least two gene sequences or regulatory elements thereof in the population of activated human T cells using a means for mutating, deleting, replacing or disrupting the genomic DNA encoding the protein of interest, resulting in reduction or elimination of the expression of CD7 and TRAC;
- and
- (d) transducing the modified activated human T cells of step (c) with an anti-CD7 CAR.
A high efficiency process for producing a population of clinical-grade anti-CD7 CAR-expressing human T cells by multiplexed editing, the process comprising:
- (a) expressing in a population of inactivated human T cells derived from a healthy human donor, a CRISPR/Cas editing system;
- (b) contacting the population of human T cells of step (a) with at least two guide polynucleotides, each targeting a polynucleotide encoding a different protein of interest, wherein a first guide polynucleotide targets CD7 and comprises an RNA sequence comprising residues 1-20 of SEQ ID NO:
- 17 or residues 1-20 of SEQ ID NO:
- 18, or an RNA sequence comprising residues 1-20 of SEQ ID NO:
- 10 or residues 1-20 of SEQ ID NO:
- 16, and a second guide polynucleotide targets TRAC and comprises the RNA sequence of SEQ ID NO:
- 19;
- (c) modifying the genomic DNA in the population of human T cells of step (b) using a means for mutating, deleting, replacing or disrupting the genomic DNA encoding the protein of interest, resulting in reduction or elimination of the cell surface expression of CD7 by at least about 97% in the resultant population when compared to a control cell population without the modifications;
- (d) transducing the activated cells of step (c) with an anti-CD7 CAR;
- and
- (e) expanding the cells of step (d), to create a population of anti-CD7 CAR-expressing human T cells having reduced risk of fratricide and reduced risk of graft versus host disease (GVHD).
(canceled)
A high efficiency means for modifying the genomic DNA in a population of human T cells that reduces the cell surface expression of CD7 and TRAC by at least about 70% in the resultant cell population when compared to a control cell population without the modifications.
A method of preparing cells for immunotherapy comprising:
- (a) modifying T cells by reducing or eliminating expression of CD7 comprising introducing into said T cells a gRNA molecule comprising an RNA sequence comprising residues 1-20 of SEQ ID NO:
- 17 or residues 1-20 of SEQ ID NO:
- 18;
- (b) modifying the T cells by reducing or eliminating expression of TRAC comprising introducing into said T cells a gRNA molecule comprising the RNA sequence of SEQ ID NO:
- 19;
- and
- (c) expanding said cells.
Dependencies are inferred from the claim text.